Danaher (DHR)
(Delayed Data from NYSE)
$267.88 USD
-6.32 (-2.30%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $267.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$267.88 USD
-6.32 (-2.30%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $267.88 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
3M Stock Trades Near 52-Week High: How Should Investors Play?
by Avisekh Bhattacharjee
MMM is making strides in electronics, automotive and aerospace, and transportation markets, which makes the stock worth a watch amid certain headwinds.
Here's Why It is Appropriate to Retain Danaher Stock For Now
by Zacks Equity Research
DHR benefits from solid momentum across its Diagnostics segment. However, increasing expenses remain a concern.
HTHIY or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HTHIY vs. DHR: Which Stock Is the Better Value Option?
Why Is Danaher (DHR) Up 2% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3M (MMM) Rises 21% in a Month: Is the Stock Worth Buying?
by Avisekh Bhattacharjee
3M's (MMM) strong prospects, driven by strength across its businesses and restructuring actions, make it an attractive pick for investors.
Danaher (DHR) Benefits From Business Strength Amid Risks
by Zacks Equity Research
Danaher (DHR) benefits from strength in the clinical diagnostics business, Abcam buyout and pro-investor policies. However, softness in its Instrument unit is concerning.
Markel's (MKL) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Markel's (MKL) Q2 results reflect improvement in earned premiums and increased net investment income.
The Zacks Analyst Blog Highlights Costco, Danaher, ServiceNow, AMREP and Autoscope
by Zacks Equity Research
Costco, Danaher, ServiceNow, AMREP and Autoscope are included in this Analyst Blog.
Top Stock Reports for Costco, Danaher & ServiceNow
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Danaher Corporation (DHR) and ServiceNow, Inc. (NOW), as well as two micro-cap stocks AMREP Corporation (AXR) and Autoscope Technologies Corporation (AATC).
3M (MMM) Q2 Earnings & Revenues Surpass Estimates, Rise Y/Y
by Zacks Equity Research
3M (MMM) reports y/y adjusted revenue growth of 1.1% in second-quarter 2024 results.
HTHIY or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HTHIY vs. DHR: Which Stock Is the Better Value Option?
3M (MMM) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Avisekh Bhattacharjee
As 3M (MMM) gears up to report second-quarter earnings, let us find out how the expectations stack up and whether it is the right time to buy the stock.
Company News for Jul 24, 2024
by Zacks Equity Research
Companies in The News Are: DHR, GM, PM, ARE
Danaher (DHR) Q2 Earnings Beat, Biotechnology Sales Dip Y/Y
by Zacks Equity Research
Danaher's (DHR) second-quarter earnings and revenues surpass estimates. However, the company's performance reflects a decrease in core sales in the Biotechnology segment.
Here's What Key Metrics Tell Us About Danaher (DHR) Q2 Earnings
by Zacks Equity Research
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 9.55% and 2.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3M (MMM) Rises 13.4% in 3 Months: How Should You Play the Stock?
by Avisekh Bhattacharjee
3M (MMM) is making strides in the diversified technology services market, which makes the stock worth a watch amid certain headwinds.
Danaher (DHR) Gears Up to Post Q2 Earnings: What to Expect
by Zacks Equity Research
Danaher's (DHR) second-quarter earnings are likely to be aided by strength in the Diagnostics and Life Sciences segment.
Danaher (DHR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Danaher (DHR) Stock Outpacing Its Conglomerates Peers This Year?
by Zacks Equity Research
Here is how Danaher (DHR) and Honeywell International Inc. (HON) have performed compared to their sector so far this year.
Is Invesco Water Resources ETF (PHO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PHO
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
by Zacks Equity Research
Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.
Top Analyst Reports for Danaher, Morgan Stanley & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Morgan Stanley (MS) and Pfizer Inc. (PFE), as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. (ELTP) and Oil-Dri Corporation of America (ODC).
Should You Invest in the Invesco Global Water ETF (PIO)?
by Zacks Equity Research
Sector ETF report for PIO